Vosoritide’s first phase 2 study shows increased growth in children with hypochondroplasia

Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital.

HHS, vaccine makers prep for first-ever three-vaccine availability with Covid, flu and RSV ahead of peak viral season

Last fall’s virus tripledemic is giving way to this year’s three-vaccine season. And the Department of Health and Human Services says it is pulling out

August 26, 2023

Global CNS Therapeutics Strategic Report 2023: Market to Reach $199 Billion by 2030 – Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth | Psychedelic Invest

The “CNS Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global CNS Therapeutics Market to Reach $199 Billion by 2030 The global market for

November 30, 2023

Study links cannabis use to genotoxicity and transgenerational health impacts

Cannabis exposure leads to genetic damage and accelerated aging, raising concerns about its transgenerational health effects and public health implications.

November 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.